Harte-Hanks Receivables

The latest receivables for HHS is $35M as of June 2026. That compares with $41M in the prior-year period — down 12.9% year over year. Investors often review this figure alongside Harte-Hanks's historical trend and sector peers before judging valuation or financial health.

Over the past year, HHS's receivables moved from $41M to $35M — a 12.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Harte-Hanks's operating scale or balance-sheet position.

A receivables figure of $35M for HHS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting HHS's receivables ($35M), review year-over-year change from $41M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Harte-Hanks's receivables against similar Consumer Discretionary names. You can also browse sector and industry screens on Stockcircle for a broader set of Consumer Discretionary companies and their key multiples and fundamentals.